Ketamine, rTMS and Short-Term Intensive Therapy: A Critical Look at the Dr. Scheib Concept

Ketamine, rTMS and Short-Term Intensive Therapy: A Critical Look at the Dr. Scheib Concept

Key question: Can a compact program of ketamine infusions, intensive psychotherapy and neuromodulation really produce lasting improvement in severe depression—and if so, for whom exactly?

In Palma there is currently a lot of talk about new forms of therapy. In front of cafés in Santa Catalina you can see people frowning at their smartphones, searching for answers. The concept presented here combines several components: ketamine-assisted psychotherapy, repetitive transcranial magnetic stimulation (rTMS), neurofeedback and other methods. It sounds modern and offers an attractive idea: to achieve as much as possible in a few weeks.

Critical analysis

Scientifically, it is known that ketamine can rapidly relieve symptoms in some patients. rTMS has a demonstrable effect for certain forms of depression. But combined programs are not automatically better than well-executed single treatments. Important questions remain: How large was the study group that reported the BDI-II decrease from an average of 29 to below 11? Was there a control group, randomized allocation, or independent follow-up? The statement that many patients remained improved a year later is encouraging, but without transparency about concurrent treatments and relapse prevention it is difficult to evaluate.

Another issue is selection bias: short-term intensive offers often attract people who can free up time and afford the costs. Who covers the expenses, how is the indication determined, and how is aftercare organized? Ketamine can cause side effects and, rarely, psychotic symptoms; this requires clear safety protocols and medical supervision. rTMS and neurofeedback are technology-driven procedures—their success depends heavily on the quality of the equipment, protocols and staff experience, a point illustrated by Virtual Reality at Hospital d'Inca.

What is missing from the public discourse

The public discussion often emphasizes the rapid effect of ketamine and less the question of long-term strategies: how can a two-week effect be carried into sustainable everyday life? Also rarely discussed: comparison with established care pathways (outpatient psychotherapy, antidepressant medication, combined treatment plans) and possible interactions with other therapies. Transparency about costs, waiting times and access is often underrepresented in reporting.

A scene from Palma

On Passeig Mallorca, where postcard weather mixes seagulls and delivery vans, I meet a woman who, after a short week-long stay in a clinic, says: "The time there was intense, almost like a small retreat. It helped me, but at home everything is different." Such voices show: intensity creates change, but everyday life tests every therapy.

Concrete solutions

1) Transparent studies: disclosure of study design, size, dropout rates and concomitant therapies. 2) Registries and aftercare: a regional registry for ketamine-assisted treatments could document side effects and long-term outcomes. 3) Involvement of primary care physicians: clear handover protocols to continuing doctors and therapists, a topic relevant to the Balearic Islands plan to place 25 psychologists in primary care. 4) Cost and access models: discussions with health insurers and private payers about reimbursable models; scholarship places for financially disadvantaged patients. 5) Qualification standards: certifications for personnel administering ketamine, rTMS or neurofeedback.

These steps would not only increase safety but also build trust—particularly important on an island community where recommendations quickly spread among friends and neighbors, as in the story of a German therapist who built a small finca near Llucmajor.

Concise conclusion

The concept combines established and newer procedures in a compact form—that is not a wrong approach. What matters, however, is not the mix itself but scientific transparency, quality control and well-thought-out aftercare. For people in Mallorca this means: stay curious, but ask concrete questions—about the evidence, the risks, the costs and returning to everyday life. Only then can a promising program become a responsible option for those who need help.

Note: This assessment is based on the available information about the therapy offering and on generally known findings about ketamine and neuromodulation. It does not replace medical advice. If you are interested in further details, direct contact via the practice's provided channels is recommended.